公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2003 | Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES | Kim S.J.; CHIEN-NAN LEE ; Lee S.Y.; Kim I.; Park J.S.; Sasagawa T.; Ko J.J.; Park S.E.; Oh Y.-K. | Gene Therapy | 23 | 23 | |
2013 | Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group | Kim S.J.; CHIUN HSU ; Song Y.-Q.; Tay K.; Hong X.-N.; Cao J.; Kim J.S.; Eom H.S.; Lee J.H.; Zhu J.; Chang K.-M.; Reksodiputro A.H.; Tan D.; Goh Y.T.; Lee J.; Intragumtornchai T.; Chng W.-J.; ANN-LII CHENG ; Lim S.T.; Suh C.; Kwong Y.-L.; Kim W.S. | European Journal of Cancer | 98 | 90 | |
2019 | A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin’s lymphoma weighing ≤70 kg | Kuruvilla J.; Tzeng C.-H.; Cho S.-G.; Kim S.J.; JIH-LUH TANG ; Su Y.; Wu J.; Vargo R.; Cheverton P. | Bone Marrow Transplantation | 2 | 2 |